The current financial score of Compugen Ltd is 6.25. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 2.60M, representing a year-over-year increase of 107.00%, while its net profit experienced a year-over-year increase of 4.58%.
The current valuation score of Compugen Ltd is 7.00. Its current P/E ratio is 6.61, which is 1278.45% below the recent high of 91.17 and 403.27% above the recent low of -20.06.
The current earnings forecast score of Compugen Ltd is 9.20. The average price target is 4.00, with a high of 13.00 and a low of 4.00.
The current price momentum score of Compugen Ltd is 5.43. Currently, the stock price is trading between the resistance level at 2.84 and the support level at 2.21, making it suitable for range-bound swing trading.
The current institutional shareholding score of Compugen Ltd is 3.00. The latest institutional shareholding proportion is 14.54%, representing a quarter-over-quarter decrease of 16.20%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 1.73% of shares outstanding, with 0.17% increase in holdings.
No risk assessment score is currently available for Compugen Ltd. The Biotechnology & Medical Research industry's average is 3.95. The company's beta value is 2.77. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.